miR-3196 acts as a Tumor Suppressor and Predicts Survival Outcomes in Patients With Gastric Cancer.
Apoptosis
Biomarkers, Tumor
/ genetics
Cell Movement
Cell Proliferation
Female
Gastrectomy
/ mortality
Gene Expression Regulation, Neoplastic
Humans
Male
MicroRNAs
/ genetics
Middle Aged
Neoplasm Invasiveness
Otx Transcription Factors
/ genetics
Prognosis
Stomach Neoplasms
/ genetics
Survival Rate
Tumor Cells, Cultured
gastric cancer
invasion
miR-3196
migration
prognosis
proliferation
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
5
1
2021
Statut:
ppublish
Résumé
Gastric cancer is one of the most common malignancies worldwide with high mortality. Therefore, identifying cancer-related biomarkers for predicting prognosis and progression of gastric cancer is essential. This study aimed to investigate the clinical value and functional role of microRNA-3196 in gastric cancer. The relative expression levels of microRNA-3196 in gastric cancer tissues and adjacent normal tissues were detected by quantitative reverse transcription-polymerase chain reaction. In this study, quantitative reverse transcription-polymerase chain reaction, cell proliferation assay, and Transwell migration and invasion assays were performed to explore microRNA-3196 expression level and its effects on cell proliferation, migration, and invasion in gastric cancer cells. The Kaplan-Meier method and multivariate Cox regression analyses were used to explore the prognostic significance of microRNA-3196 in gastric cancer. Dual-luciferase report assay was performed to validate the potential target gene regulated by microRNA-3196 in gastric cancer. The expression of microRNA-3196 was downregulated in gastric cancer tissues and cell lines. Downregulation of microRNA-3196 was associated with lymph node metastasis and Tumor Node Metastasis (TNM) stage. The Kaplan-Meier curve analysis indicated that patients with low expression of microRNA-3196 had a poor prognosis, and the Cox regression analysis results showed microRNA-3196 expression was an independent prognostic factor of gastric cancer. Moreover, overexpression of microRNA-3196 inhibited cell proliferation, migration, and invasion, while knockdown of microRNA-3196 promoted these cellular behaviors in AGS and MKN45 cells. OTX1 may be a potential target gene regulated by microRNA-3196 in gastric cancer. These results suggested that microRNA-3196 might not only a tumor suppressor in gastric cancer cells by modulating OTX1 but also might be an independent prognostic biomarker and therapeutic target of gastric cancer.
Sections du résumé
BACKGROUND
Gastric cancer is one of the most common malignancies worldwide with high mortality. Therefore, identifying cancer-related biomarkers for predicting prognosis and progression of gastric cancer is essential. This study aimed to investigate the clinical value and functional role of microRNA-3196 in gastric cancer.
METHODS
The relative expression levels of microRNA-3196 in gastric cancer tissues and adjacent normal tissues were detected by quantitative reverse transcription-polymerase chain reaction. In this study, quantitative reverse transcription-polymerase chain reaction, cell proliferation assay, and Transwell migration and invasion assays were performed to explore microRNA-3196 expression level and its effects on cell proliferation, migration, and invasion in gastric cancer cells. The Kaplan-Meier method and multivariate Cox regression analyses were used to explore the prognostic significance of microRNA-3196 in gastric cancer. Dual-luciferase report assay was performed to validate the potential target gene regulated by microRNA-3196 in gastric cancer.
RESULTS
The expression of microRNA-3196 was downregulated in gastric cancer tissues and cell lines. Downregulation of microRNA-3196 was associated with lymph node metastasis and Tumor Node Metastasis (TNM) stage. The Kaplan-Meier curve analysis indicated that patients with low expression of microRNA-3196 had a poor prognosis, and the Cox regression analysis results showed microRNA-3196 expression was an independent prognostic factor of gastric cancer. Moreover, overexpression of microRNA-3196 inhibited cell proliferation, migration, and invasion, while knockdown of microRNA-3196 promoted these cellular behaviors in AGS and MKN45 cells. OTX1 may be a potential target gene regulated by microRNA-3196 in gastric cancer.
CONCLUSIONS
These results suggested that microRNA-3196 might not only a tumor suppressor in gastric cancer cells by modulating OTX1 but also might be an independent prognostic biomarker and therapeutic target of gastric cancer.
Identifiants
pubmed: 32419651
doi: 10.1177/1533033820923427
pmc: PMC7235653
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN3196 microRNA, human
0
MicroRNAs
0
OTX1 protein, human
0
Otx Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533033820923427Références
Am J Transl Res. 2019 Aug 15;11(8):4851-4865
pubmed: 31497204
Nucl Med Biol. 2015 May;42(5):499-504
pubmed: 25682061
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3163-3171
pubmed: 31352788
Tumour Biol. 2016 Jul;37(7):9411-22
pubmed: 26781873
Exp Ther Med. 2019 Oct;18(4):2667-2674
pubmed: 31572515
Pathol Res Pract. 2019 Nov;215(11):152636
pubmed: 31558304
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Annu Rev Biochem. 2010;79:351-79
pubmed: 20533884
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8383-8390
pubmed: 30556879
Oncol Res Treat. 2018;41(1-2):47-50
pubmed: 29402861
Gastroenterol Res Pract. 2014;2014:473817
pubmed: 24982669
Onco Targets Ther. 2019 May 21;12:3965-3976
pubmed: 31190893
J Gastric Cancer. 2019 Sep;19(3):315-328
pubmed: 31598374
Cancer Biomark. 2019;24(4):477-483
pubmed: 30909187
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13
pubmed: 24618998
In Vitro Cell Dev Biol Anim. 2019 Aug;55(7):522-532
pubmed: 31264061
Dis Markers. 2019 Apr 4;2019:8949618
pubmed: 31089400
Sci Rep. 2019 Aug 20;9(1):12113
pubmed: 31431687
J Cancer. 2017 May 11;8(7):1311-1318
pubmed: 28607607
J Insur Med. 2019;48(1):5-23
pubmed: 31609640
Oncotarget. 2016 Nov 22;7(47):77764-77776
pubmed: 27780918
Br J Dermatol. 2012 Oct;167(4):847-55
pubmed: 22540308
Oncol Lett. 2019 Sep;18(3):3323-3330
pubmed: 31452811
Biosci Rep. 2019 Jul 25;39(7):
pubmed: 31266812
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Tumour Biol. 2017 Jul;39(7):1010428317714626
pubmed: 28671042
Diagn Pathol. 2019 Sep 23;14(1):107
pubmed: 31547835
IUBMB Life. 2014 May;66(5):371-7
pubmed: 24846313
Tumour Biol. 2013 Apr;34(2):1005-12
pubmed: 23292920
Oncol Rep. 2018 Oct;40(4):1907-1916
pubmed: 30066897
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7968-7977
pubmed: 31599422
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438